China's inactivated COVID-19 vaccine has shown protection from coronavirus infections in animal experiments, Xinhua reported, citing a study published in Cell magazine.
Inactivated vaccines use the killed version of the germ that causes disease.
Research into the BBIBP-CorV vaccine candidate is carried out by the Beijing Institute of Biological Products under the China National Biotec Group, the Chinese Center for Disease Control and Prevention, the Chinese Academy of Medical Sciences and other institutions.
According to Xinhua, researchers induced the pilot-scale production of the vaccine candidate to induce high levels of neutralizing antibodies in mice, rats, guinea pigs, rabbits, and non-human primates, including cynomolgus monkeys and rhesus macaques. The antibodies help protect against SARS-CoV-2.
China's Minister of Science and Technology Wang Zhigang said at a press conference on Sunday that the country will make its COVID-19 vaccine "a global public good" when it is ready for use.
A neutralizing antibody can protect a cell from a pathogen or an infectious particle by eliminating any biological effects.
In addition, the vaccine has high productivity and good genetic stability for manufacture, which research will help further evaluate in a clinical trial.
The corona virus, which first appeared in China, has killed 409,437 people worldwide. The virus infected 7,232,313 people worldwide.
The inactivated vaccine candidate was approved for clinical trials in late April, according to the China National Biotec Group.
Beijing is currently developing COVID-19 vaccines in five categories – inactivated vaccines, recombinant protein vaccines, live attenuated influenza vaccines, adenovirus vaccines and nucleic acid-based vaccines.
To date, four inactivated vaccines and one adenovirus vaccine have been approved for clinical trials.
(Except for the headline, this story was not edited by NDTV staff and published from a syndicated feed.)